PYXS Earnings Date & History
Pyxis Oncology Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 4:07 PM ET
Pyxis Oncology Inc
Biotechnology
- Next earnings date
- Wednesday, August 19, 2026
- Reporting session
- After Close
- EPS estimate
- $-0.36
- Revenue estimate
- $22,317
PYXS earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, May 14, 2026 | Q1 2026 | $-0.38 | $-0.37 | +1.7% | $0 |
| Monday, March 23, 2026 | Q4 2025 | $-0.34 | $-0.29 | +15.6% | $11.0M |
| Monday, November 3, 2025 | Q3 2025 | $-0.35 | $-0.35 | -1.4% | $0 |
| Thursday, August 14, 2025 | Q2 2025 | $-0.36 | $-0.30 | +16.4% | $2.8M |
What the market is watching in PYXS's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next PYXS earnings date?
- Pyxis Oncology Inc is scheduled to report on Wednesday, August 19, 2026 (After Close). Dates can change until the company confirms them.
- Does PYXS report before or after the market?
- The next report is scheduled after close.
- What EPS is expected for PYXS?
- Consensus EPS for the upcoming quarter is $-0.36, on revenue of $22,317.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
PYXS earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.